Precision Medicine Day Three

 

Precision 2018 Day 3

Registration opens

Beyond the genome

Precision Medicine - Other Therapeutic Areas

Beyond the Genome
08:55

Chair's opening remarks

Precision Medicine - Other Therapeutic Areas
08:55

Chair's opening remarks

Precision Medicine - Other Therapeutic Areas
09:00

Application of precision medicine and genomics to common disease

  • How AstraZeneca are applying genomics to identify new drug targets for common disease
  • The development of complimentary diagnostics to enable precision medicine
  • Future opportunities – collaboration and partnership
Beyond the Genome
09:00

Synthetic life to human longevity

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Beyond the Genome
09:25

Enabling biomarker discovery in Parkinson’s disease through Integration of multi-OMICS, clinical data and artificial intelligence

  • Use of clinical proteomic, lipidomic, and metabolomic assessment of multiple biofluids for a population health biomarker assessment of Parkinson’s Disease
  • Utilization of bAIcis, a Bayesian artificial intelligence analysis approach to integrate molecular and clinical data to identify casual drivers of Parkinson’s Disease
  • Integration of a biomarker strategy for multiple clinical unmet needs
Beyond the Genome
09:50

Development of an integrated platform for biomarker and drug target discovery using proteomics

  • The use of innovations in MS-based technologies offers a high capacity throughput proteomic profiling for clinical biochemistry purposes that can be industrialised, as has been achieved at the Stoller Biomarker Discovery Centre
  • Markers of risk in ovarian cancer have been investigated using a SWATH MS approach. We have also identified potential new curative strategies for chronic myeloid leukaemia and polycythaemia vera
  • Combined with validation platforms, this approach offers a quicker route to mechanistic detail/drug targets plus biomarkers for risk and stratification. Linkage of proteomic data to electronic health records through safe haven health informatics allows the integration of complex molecular phenotyping with endotypic data
  • Reduction in time for biomarker development for patient benefit
Precision Medicine - Other Therapeutic Areas
09:50

Development of Nusinersen: first and only treatment for spinal muscular atrophy (SMA)

  • Biology of SMA is due to deficiency in SMN protein production due to deletion or mutation in the SMN1 gene
  • Mechanism of action of nusinersen is to increase SMN protein production by modifying splicing of pre-mRNA from the SMN2 gene
  • Pivotal studies in infants and children with symptomatic SMA demonstrated benefit of treatment necessary for regulatory approval
  • Study in presymptomatic infants demonstrated benefit of treatment once patients diagnosed by newborn screening
Beyond the Genome
10:15

A gut feeling: using microbiome manipulation to treat allergic asthma

  • Understanding the human microbiome from a system perspective
  • Leveraging clinical data to establish human-first rationale for patient stratification and drug development
  • Utilizing a rationally designed microbial consortia for the treatment and prevention of allergic asthma
Precision Medicine - Other Therapeutic Areas
10:15

MRC Molecular Pathology Nodes – Progress in routes to adoption into the NHS of molecular biomarkers

  • Molecular biomarkers
  • Molecular biomarker platforms
  • Adoption into NHS
  • NICE
10:40

10:40 Networking Break

Precision Medicine - Other Therapeutic Areas
11:40

The bio-inspired artificial pancreas for treatment of diabetes in the home

  • Microchip technology can create systems inspired by biology to provide control of disease
  • The Bio-inspired Artificial Pancreas has been developed and clinically validated in people with diabetes
  • Our device can improve glucose control and reduce hypoglycaemia
  • This improves quality of life in subjects with diabetes and reduces secondary complications
Precision Medicine - Other Therapeutic Areas
12:00

Precision cardiovascular medicine

  • Challenges for cardiovascular precision medicine
  • Omics and digital health for cardiovascular medicine
  • Delivering precision cardiovascular medicine globally
Beyond the Genome
12:00

Probing disease mechanisms in ion-channel epilepsy using iPSCs, reprogramming and optogenetic approaches to provide personalized therapeutic approaches

  • The lack of easy accessibility to the cells of the nervous system has hampered progress towards the discovery of degenerative mechanisms as well as more effective treatments for neurological diseases
  • The ground-breaking technology of reprogramming, which allows for the generation of patient specific induced pluripotent stem cells (iPSCs) has created an unprecedented opportunity for a new approach towards developing cellular models of human disease
  • We employ this approach to generate cortical excitatory and inhibitory neurons as well as spinal motor neurons and astrocytes from individual patients
  • We use gene-editing techniques to introduce or fix mutations and then study the neurons we make by classical methods including immunocytochemistry, biochemistry, global genomic analysis, live cell imaging as well as by non-invasive electrophysiological recording techniques
Beyond the Genome
12:20

Cardiovascular pharmacology- Stratifying patients to improve efficacy and prevent toxicity of cardiovascular drugs

  • Anticoagulant and lipid lowering drugs will be discussed
  • Direct oral anticoagulants vs warfarin, efficacy and toxicity
  • Uptake of personalised therapies by healthcare systems
  • Health inequality and personalised medicine
Beyond the Genome
12:40

Precision medicine in severe asthma and its comorbidities: new kids on the block

  • Overview of the clinical problems: severe asthma and other severe "allergic" diseases (chronic spontaneous urticaria, nasal polyposis, atopic dermatitis);
  • New insights on endotypes and phenotypes of severe asthma and its comorbidities
  • From endotype to phenotypes, and back
  • Novel biological therapies and the need of predictive biomarkers (with novel personal and literature data)

13:00 Networking Lunch

Closing keynotes: The future of precision medicine

Thomas Hach
14:00

Precision medicine: how far and how fast can we go?

  • Current use of precision medicine in clinical practice and pharma R&D
  • Therapeutic area perspective: oncology and beyond
  • Future opportunities: cross-functional collaboration
14:20

Precision Medicine beyond Cancer amid value based compensation

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details
Karina Bienfait
14:40

Precision medicine in drug development: Leveraging genetic data to inform pipeline decisions

  • Discuss implementation of routine genomic research during drug development
  • Leveraging genomic data to achieve precision medicine
  • Discuss challenges in conducting genomic research in the context of global clinical trials
15:00

What we still need to achieve in precision medicine

Reserved for supporting partner
Please contact Erica Baeta (+44 (0)207 092 1152, erica.baeta@terrapinn.com) or Derek Cavanagh (+44 (0)207 092 1297, derek.cavanagh@terrapinn.com) for further details

15:20 End of Day 3

last published: 15/Feb/18 14:19 GMT

 

DOWNLOAD BROCHURE

 

Sign Up for Event Updates

World Precision Medicine Congress

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com